Mostrar el registro sencillo del ítem

dc.contributor.authorGonzález Valdivieso, Juan 
dc.contributor.authorBorrego, Belén
dc.contributor.authorGirotti ., Alessandra 
dc.contributor.authorMoreno, Sandra
dc.contributor.authorBrun, Alejandro
dc.contributor.authorBermejo Martín, Jesús Francisco 
dc.contributor.authorArias Vallejo, Francisco Javier 
dc.date.accessioned2025-01-15T10:43:45Z
dc.date.available2025-01-15T10:43:45Z
dc.date.issued2020
dc.identifier.citationMolecular Pharmaceutics, 2020, vol. 17, n. 5, p. 1608-1620es
dc.identifier.issn1543-8384es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/73862
dc.descriptionProducción Científicaes
dc.description.abstractThis work analyzes the immunogenicity of six genetically engineered constructs based on elastin-like recombinamers (ELRs) fused to the Gn glycoprotein from Rift Valley fever virus (RVFV). Upon transfection, all constructs showed no effect on cell viability. While fusion constructs including ELR blocks containing hydrophobic amino acids (alanine or isoleucine) did not increase the expression of viral Gn in eukaryotic cells, glutamic acid- or valine-rich fusion proteins showed enhanced expression levels compared with the constructs encoding the viral antigen alone. However, in vivo DNA plasmid immunization assays determined that the more hydrophobic constructs reduced viremia levels after RVFV challenge to a higher extent than glutamic- or valine-rich encoding plasmids and were better inducers of cellular immunity as judged by in vitro restimulation experiments. Although the Gn-ELR fusion constructs did not surpass the protective efficacy of a plasmid vaccine expressing nonfused Gn, our results warrant further experiments directed to take advantage of the immunomodulatory potential of ELR biomaterials for improving vaccines against infectious diseases.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherAmerican Chemical Societyes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.classificationRift Valley fever viruses
dc.subject.classificationDNA vaccineses
dc.subject.classificationelastin-like recombinamers (ELRs)es
dc.subject.classificationvaccine technologieses
dc.subject.classificationin vivo immunogenicityes
dc.titleA DNA Vaccine Delivery Platform Based on Elastin-Like Recombinamer Nanosystems for Rift Valley Fever Viruses
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2020 American Chemical Societyes
dc.identifier.doi10.1021/acs.molpharmaceut.0c00054es
dc.relation.publisherversionhttps://pubs.acs.org/doi/10.1021/acs.molpharmaceut.0c00054es
dc.identifier.publicationfirstpage1608es
dc.identifier.publicationissue5es
dc.identifier.publicationlastpage1620es
dc.identifier.publicationtitleMolecular Pharmaceuticses
dc.identifier.publicationvolume17es
dc.peerreviewedSIes
dc.description.projectUnión Europea-Horizonte 2020 (H2020-NMP-2014-64607)es
dc.description.projectMinisterio de Ciencia, Innovación y Universidades (DTS19/00162,MAT2016-79435-R, MAT2016-78903-R, AGL2017-82336-R)es
dc.description.projectComunidad de Madrid (2018/BAA-4370)es
dc.description.projectJunta de Castilla y León (VA317P18)es
dc.description.projectCIBER-BBNes
dc.description.projectCentro en Red de Medicina regenerativa y Terapia celular de Castilla y Leónes
dc.identifier.essn1543-8392es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/submittedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem